Liuwei Dihuang pills attenuates cognitive dysfunction in APP/PS1 mice through restoring mitochondrial homeostasis and activating the IRS/AKT/GSK3β insulin signaling pathway
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction: Alzheimer's disease (AD) features progressive cognitive decline, Aβ aggregation, neurofibrillary tangles, mitochondrial dysfunction and central insulin resistance, lacking effective disease-modifying treatments. Liuwei Dihuang Pills (LWDHP) exert neuroprotective effects, while its dual regulatory mechanisms targeting mitochondrial homeostasis and cerebral IRS/AKT/GSK3β insulin signaling remain unclear. Methods: transgenic mice were used as AD models. Morris water maze assessed spatial cognition; immunofluorescence detected Aβ and MAP2; transmission electron microscopy observed neuronal/synaptic ultrastructure; western blot quantified synaptic proteins and insulin signaling cascade molecules. Results: LWDHP significantly rescued spatial learning and memory deficits, reduced cerebral Aβ plaques and tau hyperphosphorylation. LWDHP balanced mitochondrial fusion-fission via upregulating PGC-1α/MFN2 and downregulating FIS1, elevated synaptic structural proteins (MAP2, PSD-95, SYN), restored cerebral insulin sensitivity by elevating InsR, normalizing IRS-1/AKT/GSK3β phosphorylation, and suppressing tau hyperphosphorylation. Discussion: LWDHP alleviates AD cognitive impairment through dual regulation of mitochondrial homeostasis and IRS/AKT/GSK3β insulin signaling, providing solid preclinical evidence for its anti-AD application.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Liuwei Dihuang pills attenuates cognitive dysfunction in APP/PS1 mice through restoring mitochondrial homeostasis and activating the IRS/AKT/GSK3β insulin signaling pathway
- Date Crossref
- 20/08/2026
- Éditeur
- Frontiers Media SA
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
First Affiliated Hospital of Henan University pays non établi dans la noticeÉtablissement de santé
-
Henan University of Chinese Medicine Academy of Chinese Medical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Collaborative Innovation Center of Prevention and Treatment of Major Diseases By Chinese and Western Medicine pays non établi dans la noticeInstitution
-
Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao pays non établi dans la noticeInstitution
First Affiliated Hospital of Henan University, Academy of Chinese Medical Sciences — Henan University of Chinese Medicine et Collaborative Innovation Center of Prevention and Treatment of Major Diseases By Chinese and Western Medicine, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.